Covered recipient · General Payments record
DHIMAN BASU
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$312,538.35
778 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $203,525.00 | 91 |
| Travel and Lodging | $50,272.67 | 225 |
| Consulting Fee | $35,731.50 | 16 |
| Food and Beverage | $14,990.81 | 432 |
| Honoraria | $7,800.00 | 4 |
| Education | $218.37 | 10 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 12 of 16; records 551–600 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DHIMAN BASU
NPI 1336266964 · CMS profile ID 60261
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
COLLEYVILLE, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 12 of 16; records 551–600 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=12#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DHIMAN BASU, NPI 1336266964, CMS profile ID 60261. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 16; records 551–600 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). DHIMAN BASU, NPI 1336266964, CMS profile ID 60261. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 16; records 551–600 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- DHIMAN BASU, NPI 1336266964, CMS profile ID 60261, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 12 of 16; records 551–600 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=12#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
778 matching records · $312,538.35 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 551–600 of 778.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.24 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658907327 | CMS |
| E.R. Squibb & Sons, L.L.C. | $82.38 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263261 | CMS |
| Janssen Biotech, Inc. | $18.58 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658322925 | CMS |
| Lilly USA, LLC | $1,800.00 | 04/29/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657763581 | CMS |
| Lilly USA, LLC | $675.00 | 04/29/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657766985 | CMS |
| UCB, Inc. | $89.72 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688281533 | CMS |
| AbbVie, Inc. | $218.60 | 04/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647825741 | CMS |
| E.R. Squibb & Sons, L.L.C. | $77.69 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263265 | CMS |
| E.R. Squibb & Sons, L.L.C. | $136.63 | 04/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263267 | CMS |
| Genentech, Inc. | $122.22 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681170439 | CMS |
| Mallinckrodt Enterprises LLC | $35.18 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704769905 | CMS |
| Genentech USA, Inc. | $13.13 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681223633 | CMS |
| Horizon Therapeutics plc | $5.77 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691329475 | CMS |
| Lilly USA, LLC | $39.72 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657763583 | CMS |
| Lilly USA, LLC | $3.97 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657770447 | CMS |
| Lilly USA, LLC | $428.61 | 04/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657777437 | CMS |
| Lilly USA, LLC | $7.94 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657777449 | CMS |
| Lilly USA, LLC | $229.63 | 04/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657784897 | CMS |
| ARBOR PHARMACEUTICALS, INC. | $11.53 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697366579 | CMS |
| Lilly USA, LLC | $76.56 | 04/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657773999 | CMS |
| Lilly USA, LLC | $10.62 | 04/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657774001 | CMS |
| Amgen Inc. | $91.85 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662303961 | CMS |
| Celgene Corporation | $1,012.50 | 04/20/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672753313 | CMS |
| Amgen Inc. | $27.76 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662303971 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,531.00 | 04/19/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263263 | CMS |
| Janssen Biotech, Inc. | $8.25 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658322921 | CMS |
| SANOFI-AVENTIS U.S. LLC | $100.00 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694005185 | CMS |
| Amgen Inc. | $6.56 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662303947 | CMS |
| Lilly USA, LLC | $900.00 | 04/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657770445 | CMS |
| Lilly USA, LLC | $1,800.00 | 04/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657773997 | CMS |
| Sobi, Inc | $23.32 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698087033 | CMS |
| Mallinckrodt Enterprises LLC | $1,700.00 | 04/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704769903 | CMS |
| E.R. Squibb & Sons, L.L.C. | $27.85 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263323 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.90 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263325 | CMS |
| E.R. Squibb & Sons, L.L.C. | $44.64 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263327 | CMS |
| E.R. Squibb & Sons, L.L.C. | $35.01 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263331 | CMS |
| E.R. Squibb & Sons, L.L.C. | $332.42 | 04/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263319 | CMS |
| E.R. Squibb & Sons, L.L.C. | $761.41 | 04/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263321 | CMS |
| E.R. Squibb & Sons, L.L.C. | $35.01 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263329 | CMS |
| E.R. Squibb & Sons, L.L.C. | $79.46 | 04/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263333 | CMS |
| AbbVie, Inc. | $1,925.00 | 04/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647825737 | CMS |
| Lilly USA, LLC | $16.07 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657774015 | CMS |
| Celgene Corporation | $4.06 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672780231 | CMS |
| Celgene Corporation | $244.16 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672901497 | CMS |
| Celgene Corporation | $136.91 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672901979 | CMS |
| Celgene Corporation | $50.99 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672903995 | CMS |
| Celgene Corporation | $1,823.00 | 04/10/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672905467 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.99 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651263259 | CMS |
| AbbVie, Inc. | $16.15 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647825709 | CMS |
| Janssen Biotech, Inc. | $6.36 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658322917 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $411,062.83 | 52 |
| PY2024 | Recipient | $114.46 | 1 |
| PY2024 | Principal investigator | $257,835.14 | 42 |
| PY2023 | Principal investigator | $473,106.02 | 96 |
| PY2022 | Principal investigator | $889,967.32 | 177 |
| PY2021 | Recipient | $378.10 | 1 |
| PY2021 | Principal investigator | $886,971.42 | 112 |
| PY2020 | Recipient | $2,874.16 | 3 |
| PY2020 | Principal investigator | $874,310.45 | 106 |
| PY2019 | Recipient | $3,639.50 | 1 |
| PY2019 | Principal investigator | $614,123.64 | 50 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
52 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eli Lilly and Company | $11,500.00 | 12/09/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINIC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187887550 |
| Principal investigator 1 | ABBVIE INC. | $4,455.90 | 12/04/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202527318 |
| Principal investigator 1 | ABBVIE INC. | $1,856.03 | 12/04/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202527320 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,658.00 | 11/27/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RE | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175414442 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,027.20 | 11/05/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192135287 |
| Principal investigator 1 | ABBVIE INC. | $2,187.45 | 11/04/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202520423 |
| Principal investigator 1 | ABBVIE INC. | $6,047.69 | 11/04/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202520425 |
| Principal investigator 1 | ABBVIE INC. | $1,586.35 | 10/09/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202514819 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $244.80 | 09/08/2025 | Non-covered Recipient Entity Precision Comprehensive Clinical Research Solutions | DS7011-107 | No dispute reported | 06/30/2026 | 1186252421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $244.80 | 09/08/2025 | Non-covered Recipient Entity Precision Comprehensive Clinical Research Solutions | DS7011-107 | No dispute reported | 06/30/2026 | 1223376249 |
| Principal investigator 1 | ABBVIE INC. | $3,780.90 | 09/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202507541 |
| Principal investigator 1 | ABBVIE INC. | $2,113.20 | 09/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202507543 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,564.10 | 09/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192135316 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,100.00 | 08/26/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192135294 |
| Principal investigator 1 | ABBVIE INC. | $3,068.91 | 08/05/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202501778 |
| Principal investigator 1 | ABBVIE INC. | $2,431.80 | 08/05/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202501866 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,845.60 | 08/01/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192135301 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $2,864.00 | 07/16/2025 | Non-covered Recipient Entity Precision Comprehensive Clinical Research Solutions | DS7011-107 | No dispute reported | 06/30/2026 | 1186252423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $526.00 | 07/16/2025 | Non-covered Recipient Entity Precision Comprehensive Clinical Research Solutions | DS7011-107 | No dispute reported | 06/30/2026 | 1223376243 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,060.00 | 07/16/2025 | Non-covered Recipient Entity Precision Comprehensive Clinical Research Solutions | DS7011-107 | No dispute reported | 06/30/2026 | 1223376245 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,278.00 | 07/16/2025 | Non-covered Recipient Entity Precision Comprehensive Clinical Research Solutions | DS7011-107 | No dispute reported | 06/30/2026 | 1223376247 |
| Principal investigator 1 | ABBVIE INC. | $268.35 | 07/02/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202494457 |
| Principal investigator 1 | ABBVIE INC. | $2,227.95 | 07/02/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202494789 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,527.20 | 07/02/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192129887 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,671.21 | 06/09/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE RESEARCH | A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) | No dispute reported | 06/30/2026 | 1190309244 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,736.70 | 06/04/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192129875 |
| Principal investigator 1 | ABBVIE INC. | $2,227.95 | 06/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202488801 |
| Principal investigator 1 | ABBVIE INC. | $2,842.16 | 06/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202489231 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,588.70 | 05/09/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192135308 |
| Principal investigator 1 | ABBVIE INC. | $3,109.73 | 05/06/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202481387 |
| Principal investigator 1 | ABBVIE INC. | $2,668.35 | 05/06/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202481389 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,242.84 | 04/17/2025 | Non-covered Recipient Entity AGA CLINICAL TRIALS | Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis | No dispute reported | 06/30/2026 | 1185550143 |
| Principal investigator 1 | ABBVIE INC. | $3,346.35 | 04/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202473309 |
| Principal investigator 1 | ABBVIE INC. | $930.48 | 04/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202473313 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,677.50 | 03/07/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192129881 |
| Principal investigator 1 | ABBVIE INC. | $5,548.81 | 03/06/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202457178 |
| Principal investigator 1 | ABBVIE INC. | $2,240.15 | 03/06/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202457182 |
| Principal investigator 1 | UCB SA | $9,750.00 | 03/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246659559 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,148.28 | 02/27/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC | A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus | No dispute reported | 06/30/2026 | 1190311089 |
| Principal investigator 1 | ABBVIE INC. | $736.05 | 02/05/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202444725 |
| Principal investigator 1 | ABBVIE INC. | $2,690.10 | 02/05/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202445881 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,157.00 | 01/28/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190311087 |
| Principal investigator 1 | Eli Lilly and Company | $1,362.39 | 01/27/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINIC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187887628 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,687.22 | 01/21/2025 | Non-covered Recipient Entity Precision Comprehensive Clinical Research Solutions | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) | No dispute reported | 06/30/2026 | 1235994569 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,404.46 | 01/15/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE RESEARCH | A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus | No dispute reported | 06/30/2026 | 1190309248 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,820.14 | 01/14/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC | A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) | No dispute reported | 06/30/2026 | 1190311085 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $16,450.00 | 01/13/2025 | Non-covered Recipient Entity HERITAGE RHEUMATOLOGY AND ARTHRITIS CARE | An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) | No dispute reported | 06/30/2026 | 1214124184 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,888.77 | 01/09/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE RESEARCH | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190309246 |
| Principal investigator 1 | Eli Lilly and Company | $90,824.00 | 01/07/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINIC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187887944 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $72,234.67 | 01/03/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC | Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis | No dispute reported | 06/30/2026 | 1185550145 |
| Principal investigator 1 | ABBVIE INC. | $4,833.29 | 01/02/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202435865 |
| Principal investigator 1 | ABBVIE INC. | $3,781.30 | 01/02/2025 | Non-covered Recipient Entity PRECISION COMPREHENSIVE CLINICAL | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202435878 |